This Body Protecting Compound, or BPC-157, is a peptide derived from a naturally occurring protein found in your stomachs gastric juices
Discussion The mechanism of unsuccessful therapy and resistance to pegylated INF- in HCV patients are not well understood, but there are several evidences suggesting that virus genome variability contributes to this failure.15 The estimated prevalence of HCV infection varies from 1% in Europe, 1.7% in America, and up to 5.3% in Africa.16 In Mexico HCV prevalence is 1.4% in general population,2 but in high risk populations the prevalence is higher (blood-transfused patients, health personnel, intravenous drug users, individuals with high-risk sexual behaviors)
Whether youre insured or paying cash, weve gathered tips that can help you save money, switch meds wisely, and stick with your health goals for the long haul
It comes bundled with a valuable methyl group, which PA patients often lack